2019冠状病毒病:再感染是全球健康威胁吗?

IF 1.7 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
Nepal Journal of Epidemiology Pub Date : 2021-03-31 eCollection Date: 2021-03-01 DOI:10.3126/nje.v11i1.34903
Indrajit Banerjee, Jared Robinson, Brijesh Sathian
{"title":"2019冠状病毒病:再感染是全球健康威胁吗?","authors":"Indrajit Banerjee, Jared Robinson, Brijesh Sathian","doi":"10.3126/nje.v11i1.34903","DOIUrl":null,"url":null,"abstract":"The SARS-CoV-2 virus has plagued the planet and caused unfathomable disruptions in every facet of our lives. The undue and unforeseen losses as a consequence of this pandemic will take years to quantify and even longer to curtail. This phenomenon creates an innate pressure on humans as it synergistically charges the environment to propel the movement of restarting enterprise and life as it was before the pandemic in order to curb this “loss”. \nA plethora of hurdles however are still in question. Firstly, the re-opening of enterprise and a country has to be done in a safe manner. To overcome this hurdle the development of multiple vaccinations to this novel virus has been streamlined. \nThe greatest matter in question however, is the efficacy of these vaccines and whether they will be the answer to allow a safe re-ignition of global enterprise and countries as multiple cases of reinfections have been recorded, namely reinfections post recovery from the disease. After the initiation of the immunization with both the Moderna mRNA-1273 vaccine and the Pfizer BNT162b2 vaccine, cases of infection with COVID-19 have been reported.  \nIt is evident that reinfections of the SARS-CoV-2 virus can be attributed to two major benefactors. The first being a decrease in production or failure of natural acquired immunity thus leading to the reinfection by the same strain of the virus rendering the person ill and or asymptomatic. The second benefactor is that of mutations. Mutations of the virus will predispose to reinfections as the already established naturally acquired immunity is not beneficial or useful to combat a mutated strain. It is thus poignant for cases of reinfection to be investigated thoroughly as to determine whether the reinfection was caused due to an innate lack of immunity or due to a new strain where no prior immunity existed. It must however be noted that the cases of reinfections are a rather rare event and even if a reinfection does occur, the case if usually mild and or asymptomatic. The impact of reinfection on immunization at this point of time is difficult to quantify however, initial reports do show positive signs even in cases where the vaccine is not fully effective against a mutated strain.","PeriodicalId":43600,"journal":{"name":"Nepal Journal of Epidemiology","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2021-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033645/pdf/","citationCount":"3","resultStr":"{\"title\":\"COVID-19: Are reinfections a global health threat?\",\"authors\":\"Indrajit Banerjee, Jared Robinson, Brijesh Sathian\",\"doi\":\"10.3126/nje.v11i1.34903\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The SARS-CoV-2 virus has plagued the planet and caused unfathomable disruptions in every facet of our lives. The undue and unforeseen losses as a consequence of this pandemic will take years to quantify and even longer to curtail. This phenomenon creates an innate pressure on humans as it synergistically charges the environment to propel the movement of restarting enterprise and life as it was before the pandemic in order to curb this “loss”. \\nA plethora of hurdles however are still in question. Firstly, the re-opening of enterprise and a country has to be done in a safe manner. To overcome this hurdle the development of multiple vaccinations to this novel virus has been streamlined. \\nThe greatest matter in question however, is the efficacy of these vaccines and whether they will be the answer to allow a safe re-ignition of global enterprise and countries as multiple cases of reinfections have been recorded, namely reinfections post recovery from the disease. After the initiation of the immunization with both the Moderna mRNA-1273 vaccine and the Pfizer BNT162b2 vaccine, cases of infection with COVID-19 have been reported.  \\nIt is evident that reinfections of the SARS-CoV-2 virus can be attributed to two major benefactors. The first being a decrease in production or failure of natural acquired immunity thus leading to the reinfection by the same strain of the virus rendering the person ill and or asymptomatic. The second benefactor is that of mutations. Mutations of the virus will predispose to reinfections as the already established naturally acquired immunity is not beneficial or useful to combat a mutated strain. It is thus poignant for cases of reinfection to be investigated thoroughly as to determine whether the reinfection was caused due to an innate lack of immunity or due to a new strain where no prior immunity existed. It must however be noted that the cases of reinfections are a rather rare event and even if a reinfection does occur, the case if usually mild and or asymptomatic. The impact of reinfection on immunization at this point of time is difficult to quantify however, initial reports do show positive signs even in cases where the vaccine is not fully effective against a mutated strain.\",\"PeriodicalId\":43600,\"journal\":{\"name\":\"Nepal Journal of Epidemiology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2021-03-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033645/pdf/\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nepal Journal of Epidemiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3126/nje.v11i1.34903\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/3/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nepal Journal of Epidemiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3126/nje.v11i1.34903","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/3/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 3

摘要

本文章由计算机程序翻译,如有差异,请以英文原文为准。
COVID-19: Are reinfections a global health threat?
The SARS-CoV-2 virus has plagued the planet and caused unfathomable disruptions in every facet of our lives. The undue and unforeseen losses as a consequence of this pandemic will take years to quantify and even longer to curtail. This phenomenon creates an innate pressure on humans as it synergistically charges the environment to propel the movement of restarting enterprise and life as it was before the pandemic in order to curb this “loss”. A plethora of hurdles however are still in question. Firstly, the re-opening of enterprise and a country has to be done in a safe manner. To overcome this hurdle the development of multiple vaccinations to this novel virus has been streamlined. The greatest matter in question however, is the efficacy of these vaccines and whether they will be the answer to allow a safe re-ignition of global enterprise and countries as multiple cases of reinfections have been recorded, namely reinfections post recovery from the disease. After the initiation of the immunization with both the Moderna mRNA-1273 vaccine and the Pfizer BNT162b2 vaccine, cases of infection with COVID-19 have been reported.  It is evident that reinfections of the SARS-CoV-2 virus can be attributed to two major benefactors. The first being a decrease in production or failure of natural acquired immunity thus leading to the reinfection by the same strain of the virus rendering the person ill and or asymptomatic. The second benefactor is that of mutations. Mutations of the virus will predispose to reinfections as the already established naturally acquired immunity is not beneficial or useful to combat a mutated strain. It is thus poignant for cases of reinfection to be investigated thoroughly as to determine whether the reinfection was caused due to an innate lack of immunity or due to a new strain where no prior immunity existed. It must however be noted that the cases of reinfections are a rather rare event and even if a reinfection does occur, the case if usually mild and or asymptomatic. The impact of reinfection on immunization at this point of time is difficult to quantify however, initial reports do show positive signs even in cases where the vaccine is not fully effective against a mutated strain.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Nepal Journal of Epidemiology
Nepal Journal of Epidemiology PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-
自引率
10.30%
发文量
13
期刊介绍: The Nepal Journal of Epidemiology is a international journal that encompasses all aspects of epidemiology. The journal encourages communication among those engaged in the research, teaching, and application of epidemiology of both communicable and non-communicable disease, including research into health services and medical care. Also covered are new methods, epidemiological and statistical, for the analysis of data used by those who practise social and preventive medicine. It provides the most up-to-date, original, well designed, well interpreted and significant information source in the multidisciplinary field of epidemiology. We publish manuscripts based on the following sections: 1.Short communications 2.Current research trends 3.Original research 4.Case reports 5.Review articles 6.Letter to editor
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信